Open AccessCystic Fibrosis‐related Liver Disease
Author(s) -
Baker Robert D.,
Baker Susan S.
Publication year - 2020
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002867
Subject(s) - cystic fibrosis , medicine , cystic fibrosis transmembrane conductance regulator , pathogenesis , liver disease , disease , fibrosis , pathology , gastroenterology
Up to 40% of individuals with cystic fibrosis have cystic fibrosis‐related liver disease (CFLD); however, only 5% to 10% will have clinically evident disease. With the introduction of powerful cystic fibrosis transmembrane conductance regulator (CFTR) enhancers, effective treatment for cystic fibrosis is available. The role of CFTR enhancers in liver disease is unknown at this time. The traditionally accepted theory of the pathogenesis of CFLD is being questioned. A different pathogenesis may lead to new ways to treat CFLD. The way that CFLD is diagnosed and monitored is evolving as new imaging technology become available.